Zenith Epigenetics Ltd. is a Canadian biotechnology company that was founded in 2013. The company focuses on pioneering novel therapies through advanced epigenetic research to combat autoimmune diseases and cancer. Zenith Epigenetics is dedicated to the research and development of innovative drugs through its proprietary epigenetics platform. Their drug discovery platform targets BET bromodomains, offering potential treatment options for various diseases, including autoimmune conditions and cancer. In May 2015, the company received a noteworthy $4.00M Venture Round investment, reflecting the confidence of investors in the company's potential to make significant strides in the field of biotechnology and healthcare.
Funding Stage | Amount | No. Investors | Investors | Date |
---|---|---|---|---|
Venture Round | $4.00M | - | 19 May 2015 | |
Venture Round | $4.60M | - | 23 Jul 2014 | |
Private Equity Round | $8.00M | - | 14 Mar 2014 |
No recent news or press coverage available for Zenith Epigenetics Ltd..